Alzheon Inc - Ordinary Shares

(ALZH) Trade

By |

Profile

Alzheon Inc operates as a clinical-stage biopharmaceutical company. The firm's main product is ALZ-801, an orally administered inhibitor of beta amyloid misfolding, which is in Phase III clinical trial for treating Alzheimer's disease and other neurological disorders. Its lead preclinical candidate compound includes ALZ-1903, a chemical entity and potent inhibitor of beta amyloid misfolding.

Contact Information

Website: www.alzheon.com
Main Phone: +1 508 861-7709
Address: 111 Speen Street
Address 2: Suite 306
State: MA
City / Town: Framingham
Country: USA
Postal Code: 01701

Issuer Information

Exchange: NSC
CEO: Martin Tolar
Employees: 6
NAICS: Medicinal and Botanical Manufacturing(325411)